BiotechTube
CND Life Sciences

CND Life Sciences

Scottsdale, United States· Est.
cndlifesciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $68M

Overview

CND Life Sciences is a pioneering diagnostics company focused on transforming the clinical approach to neurodegenerative diseases through its proprietary skin biopsy technology. Its flagship Syn-One Test, which has performed over 50,000 patient tests, provides objective pathological confirmation of synucleinopathies with high reported accuracy (>95% sensitivity and specificity). The company is commercial, revenue-generating, and expanding its geographic and strategic footprint, including supporting biopharma clinical trials, while navigating a competitive and reimbursement-sensitive market.

Parkinson's DiseaseSynucleinopathiesNeurodegenerative Diseases

Technology Platform

Proprietary skin biopsy and immunohistochemistry platform for detecting phosphorylated alpha-synuclein in cutaneous nerve fibers.

Funding History

2
Total raised:$68M
Series B$43M
Series A$25M

Opportunities

Significant growth is driven by the large, underserved market for accurate neurodegenerative disease diagnostics and the urgent need for biomarkers in pharmaceutical clinical trials for disease-modifying therapies.
Expansion into new geographic markets (e.g., New York) and the development of additional diagnostic applications from its skin biopsy platform present further avenues for growth.

Risk Factors

Key risks include challenges in securing consistent and adequate insurance reimbursement, emerging competition from other biomarker technologies (e.g., blood tests), and the need for ongoing physician education and adoption to integrate the test into standard clinical practice.

Competitive Landscape

CND competes in the neurodiagnostic space with companies developing alternative biomarkers for synucleinopathies, including blood-based assays (e.g., Amprion, Roche), CSF tests, and advanced imaging techniques. Its primary competitive advantage is the direct pathological visualization of the target protein via a minimally invasive procedure.

More companies in Diagnostics & Precision Medicine →More companies in United States →